Pic via Getty Images
Health & Biotech
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with news updates.
Here, we wrap up report highlights from three standout stocks in the ASX health sector.
The genomic life science company has served up a strong H2 FY25 result, with several financial and operational achievements throughout the quarter.
EZZ strengthened its brand visibility through a strategic partnership with the Australian Open, including a launch event in mainland China and a pre-event content session at Rod Laver Arena in Melbourne featuring Aussie tennis icon Mark Philippoussis.
The company also leveraged consumer insights to successfully launch four products during the quarter, aligning with evolving market demands.
EZZ expanded its retail presence by securing listings in 14 new independent pharmacies.
The company has advanced plans for entering the US market by conducting extensive market research, collaborating with key agencies, and formulating a market entry strategy scheduled for execution in H2 FY25.
EZZ said a major highlight of the quarter was its “outstanding performance during the 2025 11.11 Global Shopping Festival”, a major global shopping event offering brands the opportunity to raise awareness online.
Revenue from major marketplaces, including Douyin, Kuaishou and Tmall in China increased by 84% year-on-year to $5.9 million, which the company attributed to effectiveness of its digital marketing strategies, including focus on key opinion leaders and livestream shopping events.
EZZ exhibited at the Tax-Free World Association (TFWA) Exhibition and Conference in November in Dubai, connecting with prospective buyers and retailers across the Middle East as it looks to further broaden its international reach.
The company said it had engaged the local Australian audience through a targeted influencer campaign featuring renowned fitness expert Jono Castano to promote its healthcare products.
EZZ finished the quarter with a cash balance of $19.9m, reflecting an increase of $1.6m from the previous quarter with no debt, excluding lease liabilities.
Microba, which has technology for measuring the gut microbiome and was Morgan’s senior healthcare analyst Scott Power’s top stock pick last week, has released its Q2 FY25 result.
Microba announced cash receipts of $3.87m for the quarter, up 109% on pcp. Q2 FY25 revenue was $4.43m, up 102% on pcp with H1 revenue of $8.08m, up 147% on pcp with gains in its MetaXplore and MetaPanel test sales.
The company said MetaXplore Q2 sales in Australia of 2,560 were up 195% on pcp with growth in both ordering clinicians and orders per clinician.
The company said MetaPanel sales continued to build across all major states through the Sonic Healthcare (ASX:SHL) network with December a record sales month and January seeing a strong start to Q3 FY25.
The company has continued executing on growth plans following its 100% acquisition of microbiome testing company for healthcare professionals in the UK Invivo Clinical in late 2023.
Microba said MetaXplore sales started in the UK in October through an Early Access Program to key clinician accounts with test referral rates similar to Australia.
Microba said this demonstrated healthy initial traction and market acceptance and providing confidence to expand the program to additional clinicians, and accelerate towards full market access in H2 FY25.
The company said transition of to a new growth testing phase had impacted sales for existing testing products, however considered focus on MetaXplore was expected to translate into growth in H2 FY25 as adoption gains momentum.
Microba finished the quarter with $17.3m in cash or equivalents.
After hitting the ASX board with its IPO in November the nerve-repair biotech has reported its Q2 FY25 results with sales of $52k, representing a 260% increase on pcp.
Preliminary unaudited sales for H1 FY25 of $102K represent a 167% increase on pcp.
ReNerve said it continued to focus on expanding sales of its NervAlign nerve cuff product in its core US market but was also working to achieve growth in new jurisdictions.
In December 2024, ReNerve announced an exclusive distribution agreement with Accession Medical Supplies Co. for sales and marketing of NervAlign in Hong Kong and Macau.
It also announced it had partnered with Union MediScience B.S.C. in an exclusive distribution agreement for the sales and marketing of NervAlign Nerve Cuff in the Middle East. The agreement covers Bahrain, Saudia Arabia, Kuwait, UAE/Dubai and Qatar.
A clinical study investigating NervAlign on neurectomies repair is ongoing, with data anticipated to be released late in Q3 FY25.
The blinded study will focus on post-operative pain among two cohorts, one treated with NervAlign and the other without it.
ReNerve finished the quarter with $6.4m cash.
During the quarter Dimerix continued to progress its ACTION3 phase III trial of lead drug candidate DMX–200 in focal segmental glomerulosclerosis (FSGS).
The company completed its part two recruitment target of 144 patients randomised into the study that will trigger the next blinded interim analysis data collection in August 2025.
Dimerix said 154 patients have currently been randomised/dosed in the ACTION3 trial.
The fifth Independent Data Monitoring Committee (IDMC) review of ACTION3 trial was completed during the quarter.
During H2 FY25 expert nephrologist and co-chair of Project PARASOL Dr Laura Mariani was appointed to the ACTION3 Medical Advisory Body.
PARASOL is a collaborative, academic, and regulator-led international effort with the goal to define quantitative relationships between biomarkers like proteinuria and eGFR and long-term outcomes for FSGS patients. Dimerix hosted a technical webinar on PARASOL FSGS Insights during the quarter.
In November Dimerix announced it had teamed up with the University of Michigan’s Neptune Match study to enhance recruitment for ACTION3 Action3 in the US.
Net operating cash inflows for the December quarter were $1.83 million with Dimerix receiving a $7.9 million R&D tax incentive rebate. Dimerix ended the quarter with cash position of $21.11m at 31 December 2024.
Post quarter Dimerix announced it had entered in exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 in Japan to treat FSGS.
It is the third licensing agreement that Dimerix has successfully executed for DMX-200 in FSGS with the company saying it continued to receive strong partnering interest.
At Stockhead, we tell it like it is. While EZZ Life Science, ReNerve and Dimerix are Stockhead advertisers, they did not sponsor this article.
Health & Biotech
Health & Biotech
Health & Biotech
